+4 C°
Traffic jam:   1

2022 will be a successful year for Pfizer

22 December 2021
2 min.
2022 will be a successful year for Pfizer

Market analysts and Pfizer stock

Pfizer's (PFE) share price could hit a new high in the coming days as the US FDA is expected to receive approval for its COVID pills as early as today. Market analysts are raising their forecasts for Pfizer shares one after another.

Results from Pfizer's testing of the pill on 1,219 unvaccinated volunteers showed that Paxlovid reduced the chance of hospitalisation or death by 89% in patients with COVID-19 when treated within three days of onset of symptoms and by 85% when administered within five days. These are better results than Merck's rival drug Molnupiravir (MRK), which reduces the risk of hospitalisation or death by just 30% when treated within five days of symptom onset.

According to a report on Tuesday, the US Food and Drug Administration (FDA) may approve the anti-Covid pill from Pfizer and Merck this week. According to Bloomberg sources, the decision could be made as early as today.

Last month it was announced that the US government had agreed to buy 10 million courses of treatment with Pfizer's Paxlovid pills for $5.29bn.

On Tuesday, Pfizer announced an agreement with the UK government to supply an additional 2.5 million courses of Paxlovid treatment, subject to local approval, bringing the total number of treatment courses to 2.75 million.

Pending the possibility of approval or regulatory approval, Pfizer began production of Paxlovid earlier this year and plans to produce up to 80 million courses of treatment by the end of 2022, of which 30 million courses of treatment will be available in the first half of the year.

Pfizer will soon start generating millions of dollars from Paxlovid sales, in addition to the sales potential of booster vaccines.

This creates an additional boost to the company's revenue and earnings per share, which grew at rates of 100% and 90% in the third quarter of this year.

Thanks to its earnings growth and increased turnover of its omnibus funds, Pfizer recently announced it had acquired pharmaceutical company Arena Pharmaceuticals for $6.7bn in cash, allowing it to further expand its product range and boost sales.

In December, four top investment firms raised their target prices for Pfizer shares at once, among them: Wells Fargo, UBS, Goldman Sachs and Cowen.

Companies9 in the news

2 place
UBS Group AG
3 place
5 place
6 place
Wells Fargo
7 place
Goldman Sachs
8 place
Bloomberg L.P.
9 place
Source foto:


Rating companies
76 Mention
Dow Jones
66 Mention
33 Mention
25 Mention
24 Mention
Bloomberg L.P.
23 Mention
JPMorgan Chase
18 Mention
18 Mention
16 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director
Died this year
Born this year